| Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? | |
| | |
MedLine Citation:
|
PMID: 20382413 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Increased rates of bowel perforation in patients with recurrent epithelial ovarian cancer (EOC) treated with bevacizumab have been reported, but the risk factors for this association are uncertain. We sought to identify factors associated with bowel perforation and fistula formation in recurrent EOC patients treated with bevacizumab. METHODS: A chart review of all patients treated with bevacizumab for recurrent EOC at a single institution was performed. Pertinent patient characteristics and treatment information were collected. Univariate logistic regression was performed to analyze multiple variables. RESULTS: One hundred twelve patients who were treated with 160 different bevacizumab regimens were identified. The median age was 60 years (range, 29-78 years). Patients had received a median of 4 prior chemotherapy regimens (range, 1-10). The median number of cycles was 4 (range, 0.5-31). Ten patients (9%) were diagnosed with bowel perforations, and another 2 patients (1.8%) were diagnosed with fistulas. The 30-day mortality following perforation was 50%, with 30% of patients dying within 1 week. Patients with rectovaginal nodularity were more likely to develop a bowel perforation or fistula than those who did not have this finding, OR=3.64 (95% CI=1.1 to 12.1, p=0.04). None of the other variables were significantly associated with bowel perforations or fistula formation. CONCLUSIONS: Rectovaginal nodularity is associated with an increased risk of bowel perforation or fistula formation for patients with recurrent EOC treated with bevacizumab. Careful consideration should be given prior to initiating bevacizumab treatment in EOC patients with rectovaginal nodularity since the mortality rate with bevacizumab associated bowel perforations is 50%. |
| | |
Authors:
|
D L Richardson; F J Backes; J D Hurt; L G Seamon; L J Copeland; J M Fowler; D E Cohn; D M O'Malley |
Related Documents
:
|
19086963 - An update on the epidemiology of inflammatory bowel disease in asia. 12949433 - Perception of gastrointestinal endoscopy by patients and examiners with and without bac... 9738043 - Outbreak of pseudomonas fluorescens bacteremia among oncology patients. |
Publication Detail:
|
Type: Journal Article Date: 2010-04-10 |
Journal Detail:
|
Title: Gynecologic oncology Volume: 118 ISSN: 1095-6859 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-14 Completed Date: 2010-06-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 47-51 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, M-210 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angiogenesis Inhibitors / administration & dosage, adverse effects Antibodies, Monoclonal / administration & dosage, adverse effects* Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects* Epithelial Cells / pathology Fallopian Tube Neoplasms / drug therapy, pathology Female Humans Intestinal Perforation / chemically induced*, pathology Middle Aged Neoplasm Recurrence, Local / drug therapy*, pathology Ovarian Neoplasms / drug therapy*, pathology Peritoneal Neoplasms / drug therapy, pathology Retrospective Studies Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention.
Next Document: Surviving cervical cancer: Does health-related quality of life influence survival?